相关实验视频

Updated: Jul 6, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

NK3.3-衍生细胞外囊泡透并选择性地杀死耐治疗瘤细胞

Allyson McCune¹, Jacki Kornbluth^1,2

¹Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.

|January 11, 2024

概括

来自自然杀手 (NK) 细胞的细胞外囊 (EV) 显示出强大的抗癌活性. 这些NK3.3EVs通过诱导亡,有效地杀死耐药白血病和乳腺癌细胞,包括癌症干细胞.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞生物学细胞生物学

背景情况:

癌症治疗耐药性,转移和复发是重大临床挑战.
治疗局限性包括药物透到瘤组织的差异和癌症干细胞 (CSCs) 的存在.
从自然杀手 (NK) 细胞 (NK3.3EVs) 衍生出的细胞外囊泡 (EVs) 之前已经证明对癌症细胞系有细胞毒性作用.

研究的目的:

评估NK3.3EVs在一个更生理相关的3D乳腺癌模型中的疗效.
为了确定NK3.3EV是否能够克服白血病细胞中的化学抵抗.
评估NK3.3EVs对癌症干细胞种群的影响.

主要方法:

利用3D MCF7乳腺癌乳球模型来模拟体内条件.
为药物耐药性研究生成了一种对伊马替尼布耐药的K562慢性髓性白血病 (CML) 细胞系.
评估NK3.3EVs的细胞毒性,诱导亡 (caspase-3/-7激活),以及对CSC标记物 (CD34+/CD38-) 和基因表达的影响.

主要成果:

NK3.3EVs成功透了MCF7的乳球,并诱导了亡.
与父细胞相比,NK3.3EVs对抗伊马替尼布耐药的K562细胞表现出增强的细胞毒性,引发了亡.
NK3.3EVs降低了K562细胞中的CSC亚群和CSC相关基因表达.

结论:

NK3.3EVs对抗性和干状癌细胞具有显著的治疗潜力.
NK3.3EVs显示出作为一种具有挑战性的癌症类型的免疫治疗剂的前景.
NK3.3EVs克服耐药性和向CSC的能力需要进一步研究.

关键词:

乳腺癌乳腺癌乳腺癌癌症干细胞是癌症干细胞.细胞外囊泡中的细胞外囊泡.这种白血病是白血病.自然杀手是自然杀手.

更多相关视频

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

相关概念视频

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.